{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T15:03:56Z","timestamp":1784991836791,"version":"3.55.0"},"reference-count":40,"publisher":"Japanese Circulation Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2026,5,8]]},"DOI":"10.1253\/circrep.cr-26-0013","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T22:09:13Z","timestamp":1776895753000},"page":"788-796","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Acoramidis in Japanese Adults With Symptomatic Transthyretin Amyloid Cardiomyopathy"],"prefix":"10.1253","volume":"8","author":[{"given":"Jin","family":"Endo","sequence":"first","affiliation":[{"name":"Department of Cardiology, Keio University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Tsujita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University"},{"name":"Cardiovascular Center, Kumamoto University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chisato","family":"Izumi","sequence":"additional","affiliation":[{"name":"Department of Heart Failure and Transplantation, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Yano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kitaoka","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Geriatrics, Kochi University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Sekijima","sequence":"additional","affiliation":[{"name":"Department of Medicine, Shinshu University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Tahara","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kitasato University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Okumura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyushu University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Fukata","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Minamino","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine"},{"name":"Department of Cardiovascular Medicine, Juntendo University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen","family":"Raizner","sequence":"additional","affiliation":[{"name":"Clinical Development, Alexion, AstraZeneca Rare Disease"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[{"name":"Biostatistics, Alexion, AstraZeneca Rare Disease"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Research and Development, Alexion Pharma, GK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele F.","family":"Mercuri","sequence":"additional","affiliation":[{"name":"Clinical Development, Alexion, AstraZeneca Rare Disease"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Minamisawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Shinshu University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Ando","sequence":"additional","affiliation":[{"name":"Amyloidosis Research Centre, Sugimura Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Tromp J, Paniagua SMA, Lau ES, Allen NB, Blaha MJ, Gansevoort RT, et al. Age dependent associations of risk factors with heart failure: Pooled population based cohort study. <i>BMJ<\/i> 2021; 372: n461, doi:10.1136\/bmj.n461.","DOI":"10.1136\/bmj.n461"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Brito D, Albrecht FC, de Arenaza DP, Bart N, Better N, Carvajal-Juarez I, et al. World Heart Federation consensus on transthyretin amyloidosis cardiomyopathy (ATTR-cm). <i>Glob Heart<\/i> 2023; 18: 59, doi:10.5334\/gh.1262.","DOI":"10.5334\/gh.1262"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Kitai T, Kohsaka S, Kato T, Kato E, Sato K, Teramoto K, et al. JCS\/JHFS 2025 Guideline on diagnosis and treatment of heart failure. <i>Circ J<\/i> 2025; 89: 1278\u20131444, doi:10.1253\/circj.CJ-25-0002.","DOI":"10.1253\/circj.CJ-25-0002"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Isobe M. The heart failure \u201cpandemic\u201d in Japan: Reconstruction of health care system in the highly aged society. <i>JMA J<\/i> 2019; 2: 103\u2013112, doi:10.31662\/jmaj.2018-0049.","DOI":"10.31662\/jmaj.2018-0049"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. <i>J Am Coll Cardiol<\/i> 2019; 73: 2872\u20132891, doi:10.1016\/j.jacc.2019.04.003.","DOI":"10.1016\/j.jacc.2019.04.003"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Hashimoto T, Ikuta K, Yamamoto S, Yoshitake T, Suenaga T, Nakashima S, et al. Right ventricular to pulmonary artery uncoupling is associated with impaired exercise capacity in patients with transthyretin cardiac amyloidosis. <i>Circ J<\/i> 2024; 89: 31\u201340, doi:10.1253\/circj.CJ-24-0402.","DOI":"10.1253\/circj.CJ-24-0402"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Miyamoto M, Nakamura K, Nakagawa K, Nishii N, Kawada S, Ueoka A, et al. Prevalence and treatment of arrhythmias in patients with transthyretin and light-chain cardiac amyloidosis. <i>Circ Rep<\/i> 2023; 5: 298\u2013305, doi:10.1253\/circrep.CR-23-0022.","DOI":"10.1253\/circrep.CR-23-0022"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. <i>Orphanet J Rare Dis<\/i> 2013; 8: 31, doi:10.1186\/1750-1172-8-31.","DOI":"10.1186\/1750-1172-8-31"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. <i>N Engl J Med<\/i> 2003; 349: 583\u2013596, doi:10.1056\/NEJMra023144.","DOI":"10.1056\/NEJMra023144"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Griffin JM, Rosenblum H, Maurer MS. Pathophysiology and therapeutic approaches to cardiac amyloidosis. <i>Circ Res<\/i> 2021; 128: 1554\u20131575, doi:10.1161\/CIRCRESAHA.121.318187.","DOI":"10.1161\/CIRCRESAHA.121.318187"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Quarta CC, Fontana M, Damy T, Catini J, Simoneau D, Mercuri M, et al. Changing paradigm in the treatment of amyloidosis: From disease-modifying drugs to anti-fibril therapy. <i>Front Cardiovasc Med<\/i> 2022; 9: 1073503, doi:10.3389\/fcvm.2022.1073503.","DOI":"10.3389\/fcvm.2022.1073503"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. <i>Circulation<\/i> 2019; 140: 16\u201326, doi:10.1161\/CIRCULATIONAHA.118.038169.","DOI":"10.1161\/CIRCULATIONAHA.118.038169"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Sekijima Y, Mundayat R, Ishii T, Ando Y. The current status of the Transthyretin Amyloidosis Outcomes Survey (THAOS) in Japan. <i>Amyloid<\/i> 2019; 26: 61\u201362, doi:10.1080\/13506129.2019.1583182.","DOI":"10.1080\/13506129.2019.1583182"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Winburn I, Ishii T, Sumikawa T, Togo K, Yasunaga H. Estimating the prevalence of transthyretin amyloid cardiomyopathy in a large in-hospital database in Japan. <i>Cardiol Ther<\/i> 2019; 8: 297\u2013316, doi:10.1007\/s40119-019-0142-5.","DOI":"10.1007\/s40119-019-0142-5"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, et al. Systemic cardiac amyloidoses: Disease profiles and clinical courses of the 3 main types. <i>Circulation<\/i> 2009; 120: 1203\u20131212, doi:10.1161\/CIRCULATIONAHA.108.843334.","DOI":"10.1161\/CIRCULATIONAHA.108.843334"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO, et al. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: A report of the American College of Cardiology Solution Set Oversight Committee. <i>J Am Coll Cardiol<\/i> 2023; 81: 1076\u20131126, doi:10.1016\/j.jacc.2022.11.022.","DOI":"10.1016\/j.jacc.2022.11.022"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Minamisawa M, Konishi H, Kitano Y, Abe H, Togo K, Izumiya Y. Patient journey to transthyretin cardiac amyloidosis diagnosis: A Japanese claims database study. <i>Circ J<\/i> 2025; 89: 432\u2013441, doi:10.1253\/circj.CJ-24-0666.","DOI":"10.1253\/circj.CJ-24-0666"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Rozenbaum MH, Large S, Bhambri R, Stewart M, Whelan J, van Doornewaard A, et al. Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): A targeted literature review. <i>Cardiol Ther<\/i> 2021; 10: 141\u2013159, doi:10.1007\/s40119-021-00219-5.","DOI":"10.1007\/s40119-021-00219-5"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Ladefoged B, Dybro A, Povlsen JA, Vase H, Clemmensen TS, Poulsen SH. Diagnostic delay in wild type transthyretin cardiac amyloidosis: A clinical challenge. <i>Int J Cardiol<\/i> 2020; 304: 138\u2013143, doi:10.1016\/j.ijcard.2019.12.063.","DOI":"10.1016\/j.ijcard.2019.12.063"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Maurer MS, Grogan DR, Judge DP, Mundayat R, Packman J, Lombardo I, et al. Tafamidis in transthyretin amyloid cardiomyopathy: Effects on transthyretin stabilization and clinical outcomes. <i>Circ Heart Fail<\/i> 2015; 8: 519\u2013526, doi:10.1161\/CIRCHEARTFAILURE.113.000890.","DOI":"10.1161\/CIRCHEARTFAILURE.113.000890"},{"key":"21","unstructured":"21. US Food and Drug Administration. Vyndaqel<sup>\u00ae<\/sup> (tafamidis meglumine) and Vyndamax<sup>TM<\/sup> (tafamidis). Prescribing information. 2023. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=11685 (accessed July 31, 2025)."},{"key":"22","unstructured":"22. US Food and Drug Administration. Attruby<sup>TM<\/sup> (acoramidis) tablets. Prescribing information. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/216540s000lbl.pdf (accessed July 10, 2025)."},{"key":"23","unstructured":"23. European Medicines Agency. Vyndaqel tafamidis. 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vyndaqel (accessed July 10, 2025)."},{"key":"24","unstructured":"24. European Medicines Agency. Beyonttra acoramidis. 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/beyonttra (accessed January 14, 2025)."},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Endo J, Sano M, Izumiya Y, Tsujita K, Nakamura K, Tahara N, et al. A statement on the appropriate administration of tafamidis in patients with transthyretin cardiac amyloidosis. <i>Circ J<\/i> 2020; 84: 15\u201317, doi:10.1253\/circj.CJ-19-0811.","DOI":"10.1253\/circj.CJ-19-0811"},{"key":"26","unstructured":"26. Pharmaceuticals and Medical Devices Agency. Beyonttra\u00ae tablets, package insert [in Japanese]. 2025. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/870056_2190048F1029_1_01 (accessed July 10, 2025)."},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. <i>N Engl J Med<\/i> 2018; 379: 1007\u20131016, doi:10.1056\/NEJMoa1805689.","DOI":"10.1056\/NEJMoa1805689"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. Shah SJ, Fine N, Garcia-Pavia P, Klein AL, Fernandes F, Weissman NJ, et al. Effect of tafamidis on cardiac function in patients with transthyretin amyloid cardiomyopathy: A post hoc analysis of the ATTR-ACT randomized clinical trial. <i>JAMA Cardiol<\/i> 2024; 9: 25\u201334, doi:10.1001\/jamacardio.2023.4147.","DOI":"10.1001\/jamacardio.2023.4147"},{"key":"29","doi-asserted-by":"publisher","unstructured":"29. Nishizawa RH, Kawano H, Eguchi C, Yoshimuta T, Kojima S, Minami T, et al. Effect of \u03b2-blockers on the left ventricular strain in patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis. <i>Circ Rep<\/i> 2025; 7: 1102\u20131108, doi:10.1253\/circrep.CR-25-0140.","DOI":"10.1253\/circrep.CR-25-0140"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30. Kubota T, Kato S, Nagatomo D, Ishikita A, Nozoe M, Suematsu N. Real-world clinical impact of tafamidis on transthyretin amyloid cardiomyopathy: A decade of experience from a community-based hospital (2015\u20132024). <i>Circ Rep<\/i> 2025; 7: 442\u2013450, doi:10.1253\/circrep.CR-25-0031.","DOI":"10.1253\/circrep.CR-25-0031"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31. Izumiya Y, Kuyama N, Hanatani S, Matsuzawa Y, Usuku H, Yamamoto E, et al. Real-world clinical evidence with tafamidis in patients with transthyretin amyloid cardiomyopathy: A contemporary review. <i>Circ Rep<\/i> 2025; 7: 599\u2013603, doi:10.1253\/circrep.CR-25-0092.","DOI":"10.1253\/circrep.CR-25-0092"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32. Kuyama N, Izumiya Y, Takashio S, Usuku H, Tabira A, Oguni T, et al. Long-term effect of tafamidis on clinical parameters and prognostic predictors in patients with transthyretin amyloid cardiomyopathy. <i>Circ J<\/i> 2025; 89: 421\u2013431, doi:10.1253\/circj.CJ-24-0733.","DOI":"10.1253\/circj.CJ-24-0733"},{"key":"33","doi-asserted-by":"publisher","unstructured":"33. Eguchi C, Kawano H, Nishizawa RH, Yoshimuta T, Ohno C, Kojima S, et al. Comparing effects of tafamidis in controlling left ventricular and left atrial strains in patients with wild-type transthyretin amyloid cardiomyopathy. <i>Circ Rep<\/i> 2025; 7: 562\u2013567, doi:10.1253\/circrep.CR-25-0066.","DOI":"10.1253\/circrep.CR-25-0066"},{"key":"34","doi-asserted-by":"publisher","unstructured":"34. Ochi Y, Kubo T, Baba Y, Sugiura K, Miyagawa K, Noguchi T, et al. Early experience of tafamidis treatment in Japanese patients with wild-type transthyretin cardiac amyloidosis from the Kochi amyloidosis cohort. <i>Circ J<\/i> 2022; 86: 1121\u20131128, doi:10.1253\/circj.CJ-21-0965.","DOI":"10.1253\/circj.CJ-21-0965"},{"key":"35","doi-asserted-by":"publisher","unstructured":"35. Judge DP, Heitner SB, Falk RH, Maurer MS, Shah SJ, Witteles RM, et al. Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2019; 74: 285\u2013295, doi:10.1016\/j.jacc.2019.03.012.","DOI":"10.1016\/j.jacc.2019.03.012"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Penchala SC, Connelly S, Wang Y, Park MS, Zhao L, Baranczak A, et al. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. <i>Proc Natl Acad Sci USA<\/i> 2013; 110: 9992\u20139997, doi:10.1073\/pnas.1300761110.","DOI":"10.1073\/pnas.1300761110"},{"key":"37","doi-asserted-by":"publisher","unstructured":"37. Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. <i>N Engl J Med<\/i> 2024; 390: 132\u2013142, doi:10.1056\/NEJMoa2305434.","DOI":"10.1056\/NEJMoa2305434"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Knottnerus JA, Tugwell P. Inadequate comparators produce misleading results: The importance of good comparison practice. <i>J Clin Epidemiol<\/i> 2019; 110: v\u2013vi [Editorial].","DOI":"10.1016\/j.jclinepi.2019.04.010"},{"key":"39","doi-asserted-by":"publisher","unstructured":"39. Xu Y, Huang Z, Chang J, Yu Y, Liu C, Li J, et al. Safety and efficacy of atezolizumab in Chinese patients with previously treated locally advanced or metastatic non-small cell lung cancer: An open-label, single-arm, multicenter study. <i>Lung Cancer<\/i> 2023; 183: 107288, doi:10.1016\/j.lungcan.2023.107288.","DOI":"10.1016\/j.lungcan.2023.107288"},{"key":"40","doi-asserted-by":"publisher","unstructured":"40. Goto H, Ito S, Kizaki M, Yamaguchi M, Fukuhara N, Kato K, et al. Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed\/refractory mantle cell lymphoma. <i>Int J Clin Oncol<\/i> 2024; 29: 232\u2013240, doi:10.1007\/s10147-023-02443-6.","DOI":"10.1007\/s10147-023-02443-6"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/8\/5\/8_CR-26-0013\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T03:20:54Z","timestamp":1778296854000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/8\/5\/8_CR-26-0013\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-26-0013","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"article-number":"CR-26-0013"}}